Empagliflozin added to PBS for CKD, with or without diabetes
The addition comes just a month after the TGA approved an expanded indication for empagliflozin.
Adults with proteinuric chronic kidney disease can now access PBS-subsidised empagliflozin, regardless of their diabetes status, in addition to standard care.
On Monday, 10mg empagliflozin (Jardiance) was added to the PBS for patients with chronic kidney disease (CKD) who have been stabilised with ACEIs or ARBs for at least four weeks unless contraindicated.
The authority (streamlined) listing also requires patients to have an eGFR of 25-75mL/min/1.73m2 and a urine albumin-to-creatinine ratio (ACR) between 200mg/g and 5000mg/g.
They must not be receiving treatment with another SGLT-2 inhibitor.
